D Haritz1, D Gabel, R Huiskamp. 1. Department of Neurosurgery, University Hospital, Hamburg, Germany.
Abstract
PURPOSE: Within the European collaboration on boron neutron capture therapy (BNCT), a clinical Phase I study is being carried out to establish BNCT as an alternative treatment modality for malignant glioma (WHO III/IV). Data about the pharmacokinetics, biodistribution and toxicity of the boron compound Na2B12H11SH (BSH) are of great importance to avoid radiation damage of healthy tissue and to deliver a sufficient radiation dose. METHODS AND MATERIALS: Twenty four patients suffering from a glioblastoma multiforme entered the study to date, infused with a maximum concentration of up to 50 mg BSH/kg. Boron concentration measurements in tissues, urine, and blood were carried out, using inductively coupled plasma-atomic spectroscopy (ICP-AES) and quantitative neutron capture radiography (QNCR). A cross-calibration of these boron determination techniques was carried out. RESULTS: In tumor tissue, confirmed by histopathology of small biopsies, we found a consistently high but heterogeneous boron uptake. Necrotic parts contain much lower amounts of boron; normal brain tissue has shown no significant uptake. In skin, bone, muscle, and dura mater only small amounts of boron were found. In blood samples, we found biphasic kinetics, but with variations of the half-lives from patient to patient. The compound is mainly excreted through the urine, but an additional entero-hepatic pathway can be demonstrated. Systematic investigations revealed no toxic side effect of the intravenously administered BSH. Comparable data were obtained by using ICP-AES and QNCR for boron concentration measurements. CONCLUSION: Taking into account the radiobiological considerations of the neutron beam source, we found promising facts that BNCT could be a useful irradiation method for highly malignant brain tumors. Favorable amounts of the boron compound BSH were found in tumor tissue, whereas healthy brain tissue has shown no significant uptake.
PURPOSE: Within the European collaboration on boron neutron capture therapy (BNCT), a clinical Phase I study is being carried out to establish BNCT as an alternative treatment modality for malignant glioma (WHO III/IV). Data about the pharmacokinetics, biodistribution and toxicity of the boron compound Na2B12H11SH (BSH) are of great importance to avoid radiation damage of healthy tissue and to deliver a sufficient radiation dose. METHODS AND MATERIALS: Twenty four patients suffering from a glioblastoma multiforme entered the study to date, infused with a maximum concentration of up to 50 mg BSH/kg. Boron concentration measurements in tissues, urine, and blood were carried out, using inductively coupled plasma-atomic spectroscopy (ICP-AES) and quantitative neutron capture radiography (QNCR). A cross-calibration of these boron determination techniques was carried out. RESULTS: In tumor tissue, confirmed by histopathology of small biopsies, we found a consistently high but heterogeneous boron uptake. Necrotic parts contain much lower amounts of boron; normal brain tissue has shown no significant uptake. In skin, bone, muscle, and dura mater only small amounts of boron were found. In blood samples, we found biphasic kinetics, but with variations of the half-lives from patient to patient. The compound is mainly excreted through the urine, but an additional entero-hepatic pathway can be demonstrated. Systematic investigations revealed no toxic side effect of the intravenously administered BSH. Comparable data were obtained by using ICP-AES and QNCR for boron concentration measurements. CONCLUSION: Taking into account the radiobiological considerations of the neutron beam source, we found promising facts that BNCT could be a useful irradiation method for highly malignant brain tumors. Favorable amounts of the boron compound BSH were found in tumor tissue, whereas healthy brain tissue has shown no significant uptake.
Authors: K Hideghéty; W Sauerwein; K Haselsberger; F Grochulla; H Fankhauser; R Moss; R Huiskamp; D Gabel; M de Vries Journal: Strahlenther Onkol Date: 1999-06 Impact factor: 3.621
Authors: L Weissfloch; M Bremer; P Lemmen; T Probst; M Wagner; M Peller; T Auberger; R Senekowitsch-Schmidtke; K Tempel; M Molls Journal: Strahlenther Onkol Date: 1999-06 Impact factor: 3.621
Authors: Katalin Hideghéty; Wolfgang Sauerwein; Andrea Wittig; Claudia Götz; Philippe Paquis; Frank Grochulla; Klaus Haselsberger; John Wolbers; Ray Moss; Rene Huiskamp; Heinz Fankhauser; Martin de Vries; Detlef Gabel Journal: J Neurooncol Date: 2003 Mar-Apr Impact factor: 4.130
Authors: Sinan Wang; Charles Blaha; Raquel Santos; Tony Huynh; Thomas R Hayes; Denis R Beckford-Vera; Joseph E Blecha; Andrew S Hong; Miko Fogarty; Thomas A Hope; David R Raleigh; David M Wilson; Michael J Evans; Henry F VanBrocklin; Tomoko Ozawa; Robert R Flavell Journal: Mol Pharm Date: 2019-08-16 Impact factor: 4.939